News &

Press

venBio news

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

Feb 27, 2023

Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares

Feb 26, 2023

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Feb 24, 2023

Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

Feb 22, 2023

Harmony Biosciences reports fourth quarter and full year 2022 financial results and business updates

Feb 22, 2023

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2023

FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness

Feb 17, 2023

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2023 venBio. All Rights Reserved.